Macfarlan Smith, a subsidiary of Veranova, has completed a $10 million expansion of its mid-scale active pharmaceutical ingredient (API) manufacturing capabilities at its Edinburgh, UK facility.

The multi-purpose asset, able to handle highly active APIs and intermediates, is positioned to enable growth in the generic opioid analgesic and anti-addiction markets, while also supporting the growing demands of Veranova’s existing customer base and unlocking future growth.

The expansion is the first of two investments. The second is currently undergoing commissioning. Once completed, these expansions will represent $17 million of funding.